Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc. (OTLK), bought 10,000 shares at $0.72 ($7K) on 2020-09-22, disclosed to the SEC on 2020-09-22.
Open-market purchase of $7k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| OTLK | BUY | 2024-03-29 | $22K | — | Filing → |
| OTLK | BUY | 2022-10-11 | $43K | — | Filing → |
| OTLK | BUY | 2021-12-02 | $14K | — | Filing → |